National Comprehensive Cancer Network

About NCCN

2015 NCCN Fellows Recognition Program

By Joan S. McClure, MS, Senior Vice President, Clinical Information and Publications, NCCN

On March 15, 2015, 60 fellows attended the 2015 NCCN Fellows Recognition Program: New Horizons in Quality Cancer Care™, which was held in conjunction with the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™. The half-day meeting commenced with opening remarks followed by a presentation from Joseph V. Simone, MD, Simone Consulting.

During his presentation, Navigating the Rough Waters of Academia, Dr. Simone shared insights gained from his years as a student and renowned academic medical center leader. These insights, published as Simone’s Maxims Updated and Expanded: Understanding Today’s Academic Medical Centers, cover topics including Institutions, Leadership, Recruiting, Job Success and Satisfaction, Job Changes, The Nobility of Work, and variances between academic and private practice.  The presentation was a touchstone during the following presentations with some of other presenters acknowledging the value of Simone’s Maxims in their careers.

Following Dr. Simone, Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center, presented Peripheral T-cell Lymphomas: Evolving Treatment Options, covering  standard therapy for the most common sub-types of T-Cell Lymphoma—CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), as well as how treatment has evolved to incorporate new therapies into CHOP to tailor treatments for optimal patient outcomes.

During his presentation, Evolving Treatment Strategies for Triple Negative Breast Cancer (TNBC), Lee. S. Schwartzberg, MD, The University of Tennessee Health Science Center, discussed common characteristics of TNBC such as initial chemosensitivity and subsequent relapse patterns, as well as its shared characteristics with basal-like and BRCA-deficient tumors. New treatment strategies for TNBC, explained Dr. Schwarzberg, appear promising based on biologic sub-groups; however, enrollment in clinical trials is recommended.

Louis Burt Nabors, MD, University of Alabama at Birmingham Comprehensive Cancer Center, followed with a discussion of the advances in management of brain metastases. In his presentation, Dr. Nabors described the diagnosis and contrast of various prognostic schemas for patients with brain metastases. Dr. Nabors also compared the risks and benefits of local and regional therapies for the disease, including whole brain radiation therapy, stereotactic radiosurgery (SRS), and surgical resection, as well as the role of systemic therapy.

In the final presentation of the day, Multidisciplinary Management of Locoregional Non-Small Cell Lung Cancer (NSCLC), Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and Stephen C. Yang, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discussed the increasingly complex treatment recommendations for people diagnosed with early-stage NSCLC, including screening and diagnostic imaging and tissue acquisition, as well as personalized therapy.  Their presentation modeled multidisciplinary communication and management required for optimal care.

NCCN plans to hold the next NCCN Fellows Recognition Program during the NCCN 21st Annual Conference in 2016.